Article Text

other Versions

Download PDFPDF

Recombinant human deoxyribonuclease for the treatment of acute asthma in children
  1. Ruben Boogaard (r.boogaard{at}
  1. Erasmus MC-Sophia Children's Hospital, Netherlands
    1. Frank Smit (smitf{at}
    1. Medisch Centrum Rijnmond Zuid, Netherlands
      1. Ruud Schornagel (r.schornagel{at}
      1. Albert Schweitzer Hospital, Netherlands
        1. Anja APH Vaessen-Verberne (avaessen-verberne{at}
        1. Amphia Hospital, Netherlands
          1. Jan M Kouwenberg (j.kouwenberg{at}
          1. HagaTeaching Hospital/Juliana Children's Hospital, Netherlands
            1. Marion Hekkelaan (hekke{at}
            1. Reinier de Graaf Gasthuis, Netherlands
              1. Tom Hendriks (tom.hendriks{at}
              1. Catharina Hospital, Netherlands
                1. Sander WW Feith (sfeith{at}
                1. Sint Franciscus Gasthuis, Netherlands
                  1. Wim CJ Hop (w.hop{at}
                  1. Erasmus MC, Netherlands
                    1. Johan C de Jongste (j.c.dejongste{at}
                    1. Erasmus MC-Sophia Children's Hospital, Netherlands
                      1. Peter JFM Merkus (p.j.f.m.merkus{at}
                      1. Erasmus MC-Sophia Children's Hospital, Netherlands


                        Background: Airway obstruction in acute asthma is the result of airway smooth muscle contraction, inflammation and mucus plugging. Case reports suggest that mucolytic therapy might be beneficial in acute asthma. The aim of this study was to determine the efficacy of the mucolytic drug recombinant human deoxyribonuclease (rhDNase) in addition to standard treatment at the emergency department in children with an asthma exacerbation.

                        Methods: In a multicenter randomized double-blind controlled clinical trial, 121 children brought to the emergency room for a moderate-to-severe asthma exacerbation were randomly assigned to receive either a single dose of 5 mg nebulized rhDNase or placebo following the second dose of bronchodilators. An asthma score (scale 5 to 15) was assessed at baseline and at 1, 2, 6, 12 and 24 hours. The primary outcome variable was the asthma score 1 hour after the study medication.

                        Results: One hour after the study medication, the asthma score in the rhDNase group showed a 1.0 (0.5 to 1.6) points adjusted mean decrease from baseline (95%CI), vs. 0.7 (0.3 to 1.2) points in the placebo group; mean difference (95% CI)= 0.4 (-0.2 to 1.0) points; P=0.23. The asthma score over the study period of 24 hours also did not significantly differ between the rhDNase and placebo group (mean difference = 0.2 (-0.3 to 0.7) points, P=0.40). Duration of oxygen supplementation and number of bronchodilator treatments in the first 24 hours were similar in both groups.

                        Conclusion: Adding a single dose of nebulized rhDNase to standard treatment in the emergency room has no beneficial effects in children with moderate-to-severe acute asthma. ( number, ISRCTN81874766)

                        • asthma exacerbation
                        • controlled clinical trial
                        • dornase alfa
                        • pediatric
                        • treatment

                        Statistics from

                        Request Permissions

                        If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.